**THE MINISTRY OF HEALTHCARE OF THE RUSSIAN FEDERATION**

**INSTRUCTION**

on medical use of the medicinal product

**Grippol® plus**

**Inactivated trivalent polymer-subunit influenza vaccine**

**Marketing authorization**: № ЛСР-006981/08

**Trade name:** Grippol® plus

**Generic name**: vaccine for influenza prophylaxis [inactivated] + Azoximer bromide

**Pharmaceutical form**: suspension for intramuscular and subcutaneous injection

**Composition:**

*1 dose (0.5 ml) contains:*

Active substances:

Influenza virus antigen type

A (H1N1)\* containing hemagglutinin - 5 µg

Influenza virus antigen type

A (H3N2)\* containing hemagglutinin - 5 µg

Influenza virus antigen type B\*

containing hemagglutinin - 5 µg

Polyoxidonium® (azoximer bromide) - 500 µg

*Excipients:*

phosphate-buffered saline solution - up to 0.5 ml

Does not contain preserving agents.

*\* Influenza virus antigens strains – according to the WHO recommendations for current epidemiologic season.*

**Description.**

Colorless or light yellowish slightly opalescent fluid.

**Medicinal product characteristics.**

Vaccine comprises protective antigens (hemagglutinin and neuraminidase) obtained from purified influenza viruses A and B types propagated in the hen embryos, bound to water-soluble high-molecular immunoadjuvant which is an N-oxidized derivative of poly-1,4-ethylene piperazine (Polyoxidonium®, INN: Azoximer bromide). Vaccine antigenic formula is changed annually according to epidemiological situation and the WHO recommendations.

**Pharmacotherapeutic group**: MID-vaccine.

**ATC code**: J07BB02.

**Immunobiological properties**.

Vaccine induces high level of specific anti-influenza immunity formation. Post-vaccination protective effect usually comes in 8-12 days, and the immunity retains up to 12 months, including elderly people vaccinated. Protective anti-influenza antibody titers are detectable among 75-92% of the vaccinated of different age.

Inclusion into the vaccine product of the immune modulator Polyoxidonium® with a wide spectrum of immune pharmacological effect provides an increase of antigens immunogenicity and stability, permits to stimulate the immune memory, to decrease considerably the antigens content in vaccination dose, and to increase the organism resistance to other infections by the means of the immune status correction.

**Indications**

Specific influenza prophylaxis in children from 6 months old, adolescents, and adults without age limitation.

**Populations to be vaccinated. Vaccine is specially recommended to:**

***1. Individuals having high risk of influenza-associated complications:***

* people older 60 years old; pre-school children; schoolchildren;
* adults and children often falling ill with ARI, or those suffering from chronic somatic diseases including: central nervous system, cardio-vascular or broncho-pulmonary functions disturbances or congenital abnormalities, subjects with bronchial asthma, chronic kidney diseases, diabetes mellitus, metabolic disturbances, autoimmune diseases, allergic diseases (excluding the allergy to hen egg protein), people with chronic anemia, congenital or acquired immune deficiency, HIV-infected people;

***2. Subjects with high risk to fall ill with influenza or to transmit the influenza due to the professional occupation:***

* medical professionals, workers of educational institutions, workers of social facilities, transport, commercial workers, police, military men etc.

**Contraindications.**

* Allergy to hen protein and any vaccine ingredient.
* Allergic reactions on previous vaccination with influenza vaccines.
* Acute fever or chronic disease exacerbation (vaccination is conducted after complete recovery or in the remission period).
* Mild ARVIs, acute intestinal diseases (vaccination is performed after body temperature normalization).

**Safety precautions at application.**

Do not inject intravenously. It is necessary to have antishock products in the room where vaccination is performed. The vaccinated is to be under the care of a physician during 30 min after immunization.

**Pregnancy and lactation.**

Preclinical studies results have shown that inactivated polymer-subunit influenza vaccine does not possess embryotoxic and teratogenic effect. Doctor makes a decision about a pregnant women vaccination individually, considering the risk of contamination and possible influenza infection complications. The safest time to apply the vaccine is the second and the third trimesters.

Breast-feeding is not a contraindication to vaccination.

**Posology and method of administration.**

Vaccination is performed annually in autumn-winter season. Immunization is possible at the beginning of influenza morbidity epidemic increase period.

Children older than 3 years old, adolescents and adults are vaccinated intramuscularly or deeply subcutaneously into the upper third of shoulder outer surface (deltoid muscle). Younger children should be vaccinated intramuscularly into the front outer femur surface.

***Children aged 6 – 35 months old*** – two repeated injection of 0.25 ml with 3-4-weeks interval.

***Children aged 36 months and adults*** - a single injection of 0.5 ml.

Children who have never fallen ill with influenza and were not vaccinated can be immunized with two injections with 3-4-weeks intervals.

***To patients with immune deficiency receiving immunosuppressive therapy***, vaccine can be injected two times in the dose of 0.5 mL with 3-4-weeks intervals.

Prior to the application allow the vaccine to stand to reach room temperature and shake thoroughly. Take off the protective cap from the needle and remove the air from syringe pressing slowly the plunger keeping the syringe vertically with the needle looking up.

For immunization of children recommended to be vaccinated with the dose of 0.25 ml (1/2 of the dose) remove the half of syringe content pressing the plunger to special mark on the syringe body or red line at the label edge and inject the remaining 0.25 ml.

Open ampoules and vials and implement vaccination procedure in strict compliance with aseptic and antiseptic regulations: clean the knife for ampoules opening, ampoule neck or vial stopper with cotton moistened in 70% ethanol; open ampoule or needle the vial rubber stopper, withdraw the vaccine into disposable syringe and remove air from syringe. Clean the skin at the injection site with alcohol. Do not store the vaccine in opened ampoule or vial.

**Adverse events**

Vaccine is highly purified preparation and is well tolerated both by children and adults.

*Common (>1/100, <1/10).* Local reactions in the form of pain, hyperemia, induration and edema at the injection site. Systemic reactions: malaise, asthenia, sub-febrile temperature.

*Uncommon (>1/1000, <1/100).* Systemic reactions in the form of mild running nose, throat pain, headache, body temperature increase higher than sub-febrile.

The reactions listed usually resolve themselves in 1-2 days.

*Rare (>1/10000, <1/1000).* Allergic reactions, including immediate type reactions.

*Very rare (<1/10000).*

- nervous system: neuralgia, paresthesia, neurologic disorders;

- Locomotor system: myalgia.

Patient must be informed about the necessity to report to the physician about any severe events or those not listed in the Instruction on Use.

**Overdose**

No cases of overdose are registered.

**Interaction with other medicinal products**

Grippol® plus vaccine can be applied together with inactivated and live vaccines of National Immunization Schedule (excluding BCG and BCG-M), and together with inactivated vaccines from the Immunization Schedule according to epidemiological indications (excluding antirabic vaccines) considering the contraindications to each of the vaccines used; inject vaccines to different body sites by different syringes.

Vaccine can be injected against the background of underlying disease therapy. Vaccination of patients receiving immunosuppressive therapy (corticosteroids, cytotoxic drugs, radio-therapy) can be less effective.

**Special conditions**

On the immunization day the vaccinated undergo physical examination (medical assistant) with obligatory thermometry. Vaccination is con conducted if body temperature is higher than 37.0°С.

Ampoules, vials or syringes with damaged integrity or labeling, as well as the products with changed physical parameters (color, clarity) or after expiration date, and those stored with storage conditions incompliance are inapplicable for use.

Vaccine is not to be injected intravenously.

**Influence on ability to drive and use mechanisms.**

Grippol® plus does not influence the ability to drive and use mechanisms.

**Pharmaceutical form.**

Suspension for intramuscular and subcutaneous injection.

0.5 ml (1 dose) per disposable syringe, ampoule or bottle, air-tightly sealed with rubber stoppers crimped with aluminum caps.

1, 5 or 10 syringes per blister made of polyvinylchloride film covered with aluminum foil with polymer coating or laminated paper with polymer coating. 1 (containing 1, 5 or 10 syringes) or 2 (containing 5 syringes) blisters together with Instruction on Use per carton pack. 5 ampoules or bottles per polyvinylchloride film blister. 1 or 2 blisters together with Instruction on Use per carton pack.

Or 5 or 10 ampoules or bottles without blister together with Instruction on Use per carton pack.

**Storage conditions.**

Protected from light in a dry place at temperature of 2 °С – 8 °С.

**Do not freeze**! Do not apply the product which had been frozen.

Keep out of the reach of children.

**Shipping conditions**

In a dry protected from light place at a temperature of 2 to 8 ° C in conditions that exclude freezing.

Transportation is allowed at a temperature not exceeding 25 ° С for no more than 24 hours.

**Shelf life**

1 year. Do not use the product after the expiry date.

**Pharmacy purchasing terms.**

Prescription product.

**Legal body to whom Marketing Authorization was granted**

Marketing Authorization Holder and Manufacturer:

NPO Petrovax Pharm, LLC

Legal address and address of manufacture:

Sosnovaya str., 1, Pokrov village, Podolsk city, Moscow region, Russian Federation, 142143, tel.: +7(495 926-21-07, E-mail: info@petrovax.ru;

Send reclamations on medicinal product quality concerning physical properties, package and information about the cases of increased reactogenicity or cases of postvaccinal complications development with obligatory indication of batch number and date of manufacture and subsequent provision of medicinal documentation to the manufacturer NPO Petrovax Pharm, LLC.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  |  |